Ionis Pharma highlights achievements, advancement on Investor Day

 

• Ionis Pharmaceuticals (NASDAQ:IONS) has the potential to launch more than six new products through 2026.
• The expectation is that the implementation of this strategy will drive double-digit revenue growth and substantial earnings growth.
• Company seems to be positioned for a strong 2021 and beyond.
• Company estimates the total market opportunity for the indications targeted by its pipeline is well in excess of $15B, with a significant portion from its wholly owned medicines.
• "In 2020, we pursued an aggressive agenda focused on building our commercial plans and capabilities, progressing the Ionis-owned pipeline, advancing our technology and growing our leadership position in RNA-targeted therapeutics. We are pleased to say that we delivered against all these objectives. We invested in building our commercial plans and capabilities and began implementation. These actions were accelerated through the acquisition of our commercial affiliate Akcea. We have also progressed and substantially expanded the Ionis-owned pipeline. In addition, we have six Phase 3 trials underway, initiated 13 Phase 2 trials, achieved multiple, positive clinical proof-of-concept readouts, and advanced new delivery platforms." said Brett P. Monia, Ph.D., CEO.
• Press Release
• https://seekingalpha.com/news/3642883-ionis-pharmaceuticals-highlights-achievements-and-advancement-on-investor-day